We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology 2 as our first CGM partner, marking a significant milestone as we bring our ...

Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor.

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

A year to the day after declaring the FDA’s clearance of its automated insulin pump, Sequel Med Tech announced that its first connected continuous glucose monitor will be Abbott’s FreeSty | Greenlit ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

Ypsomed and CamDiab today announced the launch of the mylife CamAPS FX app for automated insulin delivery on iOS platforms.

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

Abbott Laboratories (NYSE:ABT) specializes in medical devices, diagnostics, nutrition, and branded generic pharmaceuticals. In diabetes care, its flagship FreeStyle Libre system, a continuous ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...